| pubmed-article:10785238 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0015915 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0023610 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0733758 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0019927 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0547040 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0209366 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0949385 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0439792 | lld:lifeskim |
| pubmed-article:10785238 | lifeskim:mentions | umls-concept:C0557702 | lld:lifeskim |
| pubmed-article:10785238 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10785238 | pubmed:dateCreated | 2000-6-20 | lld:pubmed |
| pubmed-article:10785238 | pubmed:abstractText | OBJECTIVE: To study whether minimal interference in the process of selection of the single dominant follicle may serve as the basis for a simplified ovarian stimulation regimen for IVF. DESIGN: Single-center randomized pilot study. SETTING: Tertiary referral fertility center. PATIENT(s): Fifteen normo-ovulatory patients with a regular indication for IVF. INTERVENTION(s): Ovarian stimulation for IVF was begun with 100 or 150 IU/d recombinant FSH starting on cycle day 5. From cycle day 8 or later, cotreatment was begun with 0.25 mg/d GnRH antagonist. No luteal support was provided. MAIN OUTCOME MEASURE(s): Total number of dominant follicles and characteristics of the endocrine cycle. RESULT(s): Multiple follicle development occurred in five of eight patients in the 100-IU group and in all seven women in the 150-IU group. Follicular phase and luteal phase lengths were normal, but the endocrine profile was abnormal. CONCLUSION(s): A fixed daily dose of 150 IU recombinant FSH starting in the midfollicular phase resulted in ongoing growth of a restricted number of dominant follicles and sufficient oocytes retrieved to lead to ET. A marked reduction in the total amount of gonadotropins administered compared with standard treatment was achieved. Withholding luteal support did not exclude pregnancies. | lld:pubmed |
| pubmed-article:10785238 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10785238 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10785238 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10785238 | pubmed:month | May | lld:pubmed |
| pubmed-article:10785238 | pubmed:issn | 0015-0282 | lld:pubmed |
| pubmed-article:10785238 | pubmed:author | pubmed-author:de JongDD | lld:pubmed |
| pubmed-article:10785238 | pubmed:author | pubmed-author:FauserB CBC | lld:pubmed |
| pubmed-article:10785238 | pubmed:author | pubmed-author:MacklonN SNS | lld:pubmed |
| pubmed-article:10785238 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10785238 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:10785238 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10785238 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10785238 | pubmed:pagination | 1051-4 | lld:pubmed |
| pubmed-article:10785238 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:meshHeading | pubmed-meshheading:10785238... | lld:pubmed |
| pubmed-article:10785238 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10785238 | pubmed:articleTitle | A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix. | lld:pubmed |
| pubmed-article:10785238 | pubmed:affiliation | Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. | lld:pubmed |
| pubmed-article:10785238 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10785238 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10785238 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10785238 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10785238 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10785238 | lld:pubmed |
